Celyad Oncology SA (NASDAQ:CYAD – Get Rating)'s share price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.88 and traded as low as $1.79. Celyad Oncology shares last traded at $1.79, with a volume of 8,115 shares changing hands.

Celyad Oncology Stock Down 8.7 %

The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.58 and a current ratio of 1.71. The business's 50 day simple moving average is $1.88 and its 200-day simple moving average is $2.08.

Celyad Oncology Company Profile

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Read More

• Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
• Could Nike Stock be Oversold, but Still Overvalued?
• Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
• Will Royal Caribbean's Broadband Partnership Drive Revenue?
• Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
• DocuSign Has Important Issues to Address When it Reports Earnings

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.